Response by Lewis and de Lemos to Letter Regarding Article, "racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study"

Alana A. Lewis; James A. De Lemos

doi:10.1161/CIRCULATIONAHA.120.048688

Response by Lewis and de Lemos to Letter Regarding Article, "racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study"

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E69-E70
Journal	Circulation
Volume	142
Issue number	5
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.120.048688
State	Published - Aug 4 2020

Funding

Dr de Lemos reports grant support from Roche Diagnostics and Abbott Diagnostics; reports consulting fees from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Corporation, Novo Nordisk, Amgen, Regen-eron, and Esperion; and is a co-owner of a patent (US patent application number 15/309,754) titled “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr Lewis has no relationships to disclose.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.120.048688

Cite this

@article{c53e1a14d0774aa5bcc9b3d4907e22d9,

title = "Response by Lewis and de Lemos to Letter Regarding Article, {"}racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study{"}",

author = "Lewis, {Alana A.} and {De Lemos}, {James A.}",

note = "Funding Information: Dr de Lemos reports grant support from Roche Diagnostics and Abbott Diagnostics; reports consulting fees from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Corporation, Novo Nordisk, Amgen, Regen-eron, and Esperion; and is a co-owner of a patent (US patent application number 15/309,754) titled “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr Lewis has no relationships to disclose.",

year = "2020",

month = aug,

day = "4",

doi = "10.1161/CIRCULATIONAHA.120.048688",

language = "English (US)",

volume = "142",

pages = "E69--E70",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Response by Lewis and de Lemos to Letter Regarding Article, "racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure

T2 - A Multicohort Study"

AU - Lewis, Alana A.

AU - De Lemos, James A.

N1 - Funding Information: Dr de Lemos reports grant support from Roche Diagnostics and Abbott Diagnostics; reports consulting fees from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Corporation, Novo Nordisk, Amgen, Regen-eron, and Esperion; and is a co-owner of a patent (US patent application number 15/309,754) titled “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr Lewis has no relationships to disclose.

PY - 2020/8/4

Y1 - 2020/8/4

UR - http://www.scopus.com/inward/record.url?scp=85089356918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089356918&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.120.048688

DO - 10.1161/CIRCULATIONAHA.120.048688

M3 - Letter

C2 - 33210941

AN - SCOPUS:85089356918

SN - 0009-7322

VL - 142

SP - E69-E70

JO - Circulation

JF - Circulation

IS - 5

ER -

Response by Lewis and de Lemos to Letter Regarding Article, "racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study"

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this